Day: November 7, 2020

TORONTO, Nov. 06, 2020 (GLOBE NEWSWIRE) — Cryptologic Inc. (“Cryptologic” or the “Company”) (CSE:CRY) today announces its financial results for the quarter ended September 30, 2020. Selected financial information of the Company for the three and nine months ended September 30, 2020 and 2019 and the year ended December 31, 2019 is set forth below:The Company reported a net loss of $1.1 million for the quarter ended September 30, 2020 as compared to net income of $2.1 million for the same quarter in the previous year. The Company reported a net income of $1.9 million for the nine months ended September 30, 2020 as compared to a net loss of $11.7 million for the same period in the previous year.On April 8, 2020, the Company announced that it sold the shares of its wholly-owned subsidiary 9376-9974 Quebec Inc. to HIVE Blockchain Technologies...

CAMBRIDGE, Mass. and TOKYO, Nov. 06, 2020 (GLOBE NEWSWIRE) — Today, the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted 1 yes, 8 no and 2 uncertain on the question, “Does Study 302 (EMERGE), viewed independently and without regard for Study 301 (ENGAGE), provide strong evidence that supports the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”. The Advisory Committee also voted 0 yes, 7 no and 4 uncertain on the question, “Does Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”, and 5 yes, 0 no and 6 uncertain on the question, “Has the Applicant presented strong evidence of a pharmacodynamic effect of aducanumab on Alzheimer’s disease pathophysiology?”. Finally, the Advisory...